aTyr Pharma Inc (LIFE)
aTyr Pharma is a biotherapeutics company engaged in the discovery and development of medicines based on biological pathways. Co.'s primary therapeutic candidate efzofitimod, which is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable region of a human antibody. In parallel with Co.'s clinical development of efzofitimod, Co. has been improving its discovery pipeline of NRP2 antibodies and tRNA synthetases. Co.'s investigational new drug candidate ATYR2810, which is a humanized monoclonal antibody that blocks the interaction between NRP2 and one of its primary ligands, vascular endothelial growth factor.
|
Free LIFE Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.67 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: LIFE Stock Forecast Based on Zacks ABR data; powered by Xignite |